company background image
NEO logo

NeoGenomics NasdaqCM:NEO Stock Report

Last Price

US$14.44

Market Cap

US$1.9b

7D

-4.6%

1Y

-19.3%

Updated

22 May, 2024

Data

Company Financials +

NEO Stock Overview

Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.

NEO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

NeoGenomics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeoGenomics
Historical stock prices
Current Share PriceUS$14.44
52 Week HighUS$21.22
52 Week LowUS$11.03
Beta1.12
1 Month Change7.60%
3 Month Change-12.22%
1 Year Change-19.33%
3 Year Change-64.03%
5 Year Change-31.92%
Change since IPO455.38%

Recent News & Updates

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Recent updates

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Dec 26
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Aug 23
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16
Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10
We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22
Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11
Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07
Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

NeoGenomics: Gambling On Growth

Dec 16

NeoGenomics: Profitability Headwinds Compress Valuation, Shares

Sep 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Sep 24
Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

NeoGenomics: Strong Growth Potential For A Leader In Cancer Diagnostic Testing

Jul 02

NeoGenomics completes Inivata acquisition

Jun 18

Shareholder Returns

NEOUS HealthcareUS Market
7D-4.6%0.09%-0.2%
1Y-19.3%6.9%28.2%

Return vs Industry: NEO underperformed the US Healthcare industry which returned 6.9% over the past year.

Return vs Market: NEO underperformed the US Market which returned 27.7% over the past year.

Price Volatility

Is NEO's price volatile compared to industry and market?
NEO volatility
NEO Average Weekly Movement6.1%
Healthcare Industry Average Movement6.6%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: NEO has not had significant price volatility in the past 3 months.

Volatility Over Time: NEO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20012,100Chris Smithwww.neogenomics.com

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

NeoGenomics, Inc. Fundamentals Summary

How do NeoGenomics's earnings and revenue compare to its market cap?
NEO fundamental statistics
Market capUS$1.89b
Earnings (TTM)-US$84.23m
Revenue (TTM)US$610.66m

3.0x

P/S Ratio

-21.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NEO income statement (TTM)
RevenueUS$610.66m
Cost of RevenueUS$355.40m
Gross ProfitUS$255.26m
Other ExpensesUS$339.49m
Earnings-US$84.23m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.66
Gross Margin41.80%
Net Profit Margin-13.79%
Debt/Equity Ratio58.4%

How did NEO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.